Maturitas
Volume 57, Issue 1 , Pages 3-5 , 20 May 2007

Postmenopausal hormone therapy: The way ahead

References 

  1. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–613
  2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits from the women's Health Initiative in healthy postmenopausal women. JAMA. 2002;288:321–333
  3. U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med. 2005;142:855–860
  4. Grady D. Management of menopausal symptoms. N Engl J Med. 2006;355:2338–2347
  5. Manson JE, Bassuk SS, Herman SM, et al. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause. 2006;13:139–147
  6. Lobo R. Appropriate use of hormones should alleviate concerns of cardiovascular and breast cancer risk. Maturitas. 2005;51:98–109
  7. Pines A. WHI and aftermath: looking beyond the figures. Maturitas. 2005;51:48–50
  8. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006;166:357–365
  9. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006;295:1647–1657
  10. Nabel EG. The Women's Health Initiative. Science. 2006;313:1703

PII: S0378-5122(07)00061-8

doi: 10.1016/j.maturitas.2007.02.001

Maturitas
Volume 57, Issue 1 , Pages 3-5 , 20 May 2007

Article Tools